Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors...
Nemaura Medical reported revenue of $0 for fiscal year 2023, and net income of -$14.14 million. In Q3 2024 (the quarter ended December 31, 2023) revenue was $0. Its market capitalization was $4,035 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2023; market data as of October 8, 2026.
No profile data available.